Trial Profile
Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Dermatomyositis; Polymyositis
- Focus Biomarker; Therapeutic Use
- Acronyms RIM
- 09 Nov 2021 Results (n=194) assessing the effect of rituximab on IgG levels of DM/PM/JDM patients and the association of IgG levels with infections retrospectively using the Rituximab in Myositis (RIM) study data, presented at the ACR Convergence 2021.
- 21 Oct 2014 New source identified and integrated (ClinicalTrials.gov record: NCT00106184)
- 21 Oct 2014 New source identified and integrated (ClinicalTrials.gov record: NCT00106184)